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Objective: To test the hypothesis that our inner city obstetric patients who have been infected with sexually
transmitted diseases (STDs) will have a higher prevalence of hepatitis C virus infection than the general
population and to identify specific risk factors and high-risk groups.
Methods: All patients in our prenatal clinic (July 1997–April 1999) who tested positive for one or more STDs
were asked to return for hepatitis C antibody testing. Medical charts of all patients who returned for hepatitis C
testing were reviewed.
Results: A total of 106 patients with STDs were tested for hepatitis C. Positive screening tests for anti-hepatitis C
antibody were found in 6.6% (7/106) of the patients (95% CI = 2.7–13.1%). This frequency is significantly
higherthanthehepatitisCprevalence(1.8%)inthegeneralUnitedStatespopulation(p = 0.006).Multiplelogistic
regression analysis confirmed only older age (p = 0.016) and positive HIV status (p = 0.023) to be significant
predictors of hepatitis C infection.
Conclusions: Inner city STD-infected obstetric patients are at high risk for hepatitis C infection compared with
the general population. Increasing age and HIV-positive status are risk factors which are significantly associated
with hepatitis C infection.
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Infection with the hepatitis C virus is the most
common blood-borne infection in America.
The prevalence in the general United States popu-
lation is 1.8%. It is estimated that over 3.9 million
Americans are currently infected and that 95% of
these individuals are unaware of their infection1.
About 75% of acute hepatitis C infections are
asymptomatic; 80% of these patients will go on to
have chronic infection1. Of patients with chronic
infection, 25% will develop cirrhosis and 20%
will progress to hepatocellular carcinoma in
an average of 25 years1. Therefore, early identifi-
cation of hepatitis C infection is important in
developing programs for prevention and possible
treatment with anti-viral therapy.
Universal screening for hepatitis C infection
has not yet been recommended due to the low
prevalence rate in the general population. The
Centers for Disease Control and Prevention1
(CDC) have recommended that hepatitis C
screening should be offered to patients at high risk
for infection. Routine screening for hepatitis C
infection is recommended for the following high-
risk groups: patients with a history of injecting
drug use, patients who received blood trans-
fusion or organ transplants before 1992, patients
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 2003 The Parthenon Publishing Group 191who received clotting factor concentrates before
1987, patients with a history of chronic hemo-
dialysis or chronic liver disease, and children born
to hepatitis C-infected women. Hepatitis C is
primarily transmitted via percutaneous exposure –
the most commonly reported risk factor is the
use of parenteral drugs (60%). Blood transfusion
(which accounted for the majority of hepatitis C
infections acquired more than 10 years ago) is
currently responsible for only a small percentage
of cases.
Sexual transmission of hepatitis C seems to
occur1–3. Data are still lacking, however, regard-
ing the extent to which sexual activity and
STDs contribute to the transmission of the
hepatitis C virus1. Intranasal drug use has also
been reported as a risk factor for hepatitis C
infection4. Due to the lack of consistent data,
the CDC have determined that hepatitis C
screening is of ‘uncertain’ need for those with a
history of multiple sexual partners, a history of
STDs or intranasal cocaine or other non-injecting
drug use.
Both STDs and substance abuse are quite
common among our inner city population. We
undertook this study to test the hypothesis that
hepatitis C infection would be more common
in our inner city STD-infected pregnant patients
than in the general United States population.
Our goals were: (i) to define the prevalence of
hepatitis C in our STD-infected pregnant patients
and (ii) to identify specific high risk groups
in which screening for hepatitis C would be
most productive.
SUBJECTS AND METHODS
All pregnant women in our clinic undergo
routine testing for STDs as part of routine pre-
natal care. This testing includes cervical swabs
for chlamydia and gonorrhea and serum tests for
syphilis, hepatitis B, and HIV. With the prior
approval of our study protocol by our Institutional
Review Board, all pregnant patients receiving care
at University Women’s Health Center, New
Jersey Medical School, Newark, from July 1997 to
April 1999 who tested positive for one or more
STDs during prenatal visits were asked to return
for hepatitis C screening. Criteria for STDs were
defined as positive tests for: chlamydia by poly-
merase chain reaction (PCR), gonorrhea by PCR
or Thayer–Martin agar culture (as required by
insurance carrier), syphilis by VDRL confirmed
by fluorescent treponeme antibody, hepatitis B
by B surface antigen or B core antibody or
HIV by enzyme-linked immunosorbent assay
(ELISA)confirmedwithWesternblot.Allpatients
who returned for the requested hepatitis C
screening test were included in our analysis.
The anti-hepatitis C antibody screening
test used by our laboratory was an enzyme
immunoassay (hepatitis C virus encoded antigen–
recombinant c100-3, HC-31 and HC-34, Abbott
hepatitis C EIA 2.0, 1992, Abbott Laboratories,
Abbott Park, IL). Patients with known hepatitis C
infection were excluded from the study. If
the screening hepatitis C antibody test was
positive, then the patients were asked to return
for confirmatory testing with a recombinant
immunoblot assay (hepatitis C virus encoded
antigen–recombinant 5–1–1, c100–3, c33c and
c22–3, Chiron RIBA hepatitis C 2.0 SIA, 1995,
Chiron Corporation, Emeryville, CA).
We then reviewed the patients’ charts and
laboratory test results to collect information on
STDs and demographic data including: age,
gravidity, parity, number of sexual partners in
the past 6 months and any history of drug use.
Drug use was defined as chart documentation of
a patient self-report of illicit drug use during
an encounter with their health care provider.
This was broken down into injection use (intra-
venous or skin-popping) or intranasal use.
Data analysis was performed using StatXact
and LogXact statistical software. Confidence
intervals for prevalence rates were based on the
binomial distribution. The prevalences of various
infections in different groups were compared
using Fisher’s Exact Test. The rank sum test was
used to compare continuous and ordered variables
(age, parity) of hepatitis C-infected women and
hepatitis C-negative women. Multiple logistic
regression was used to test the simultaneous
significance of variables as independent risk
factors for hepatitis C infection. The criterion
forstatisticalsignificancewastwo-tailedp < 0.05.
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Table 1 presents the prevalence of various STDs
in the population tested. A total of 106 STD-
infected pregnant patients were screened for
hepatitis C antibody and seven had a positive
screening test, giving a prevalence of hepatitis C
of 6.6%. This is significantly higher than the
control general United States population with a
reported 1.8% prevalence (95% CI = 2.7–13.1%,
p = 0.006).
Chlamydia was the most common STD in the
studied population, identified in 56% of our
STD-positive patients. This was followed in
frequency by hepatitis B, gonorrhea and HIV
infection. Hepatitis C infection was the fifth most
common infection in this studied population.
HIV infection was identified with almost the
same frequency as hepatitis C (6.9 versus 6.6%).
Syphilis testing had a much lower yield (3.8%)
than hepatitis C screening.
Table 2 presents the population characteristics
of our STD-positive pregnant patients who did
or did not have hepatitis C infection. Patients
testing positive for hepatitis C infection were
significantly older (median age 28 versus 21
years, p = 0.001). Patient age alone identified a
group of women at high risk for hepatitis C
infection; of women less than or equal to 24
years, only 1/74 (1.35%) had hepatitis C, while
6/32 (18.75%) of those greater than or equal to
25 years were infected. They also had a signifi-
cantly greater number of pregnancies than the
hepatitis C-negative group (median gravidity of
3 versus 2, p = 0.03). Hepatitis C-positive women
also tended to have more livebirths (median
parity of 1.5 versus 0), although this trend did
not reach statistical significance.
Table 3 presents the influence of various risk
factors upon a patient’s chance of testing positive
for hepatitis C. Univariate analysis clearly demon-
strated significant positive associations between
hepatitis C infection and histories of intravenous
drug use, nasal drug use, or any type of illicit drug
use and positive testing for hepatitis B and HIV.
Odds ratios for hepatitis C infection in obstetric
patients with these risk factors ranged from 6.3
to 73. Conversely, positive testing for other
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STD
Prevalence of
STD (%) STD-infected
Total number
tested
Chlamydia
Hepatitis B
Gonorrrhea
HIV
Hepatitis C
Syphilis
56
31
16
6.9
6.6
3.8
59
33
17
7
7
4
106
106
106
102
106
106
Table 1 Prevalence of the different STDs in the study
population
Population
characteristic
Hepatitis
C-positive median
(95% CI)
Hepatitis
C-negative
median (95% CI)
Rank sum
test
p-value
Age
Gravidity
Parity
28 (21–45)
(n = 7)
3 (2–6)
(n = 6)
1.5 (0–3)
(n = 6)
21 (14–39)
(n = 99)
2 (1–11)
(n = 94)
0 (0–6)
(n = 94)
–
0.001
–
0.031
–
0.17
Table 2 Demographic characteristics of patients sero-
positive for hepatitis C and patients who are
seronegative
Risk factor % hep C in those ‘with’ risk factor % hep C in those ‘without’ risk factor Odds ratio p-value
Any drug use
IVDA
Nasal drug use
HIV
Hepatitis B
Gonorrhea
Chlamydia
Syphilis
28 (5/18)
57 (4/7)
33 (4/12)
57 (4/7)
15 (5/33)
0 (0/17)
2 (1/59)
0 (0/4)
3 (2/80)
2 (1/55)
2 (1/50)
3 (3/95)
3 (2/73)
8 (7/89)
13 (6/47)
7 (7/102)
15
73
25
41
6.3
(0)
0.12
(0)
0.002
0.001
0.004
0.001
0.029
0.59
0.043
1.0
Note that chlamydia infection was associated with a lower risk of hepatitis C
Table 3 The prevalence of hepatitis C infection in patients with or without studied risk factorsSTDs had either no association (gonorrhea,
syphilis) or a negative association (chlamydia)
with hepatitis C infection.
Multiple logistic regression analysis of the
factors associated with hepatitis C infection
confirmed only patient age (p = 0.016) and HIV-
positivity (p = 0.023) as significant predictors of
hepatitis C infection.
DISCUSSION
This study found that STD-infected inner city
obstetric patients who returned for hepatitis C
screening had a relatively high prevalence of
hepatitis C infection (6.6%). These patients, there-
fore, represent a high-risk group in whom
screening for hepatitis C should have a significant
yield. Hepatitis C testing was far more likely
to identify occult infection than screening for
syphilis.
Several interesting associations were identified
in our analysis. Age was significantly associated
with positive hepatitis C status. Increasing age has
been found to be an independent risk factor for
hepatitis C in a variety of populations5–9. Several
previous studies of general obstetric clinic patients
have also noted older women to be more likely
to harbor hepatitis C10–13. It is currently unclear
whether this association represents a cohort effect
or merely that older women have an increasing
number of lifetime opportunities to be exposed
to this frequently undiagnosed, indolent disease
through a variety of mechanisms. Regardless of
the reason, it seems clear that women under the
age of 25 are at lower risk for hepatitis C than
women over the age of 25.
Hepatitis C was very strongly linked with
HIV-positive status. Both diseases are spread
efficiently through parenteral exposure and are
both commonly seen in intravenous drug
abusing populations. Previous work has suggested
that pregnant women positive for both HIV
and hepatitis C are more likely to transmit
hepatitis C to their infants than HIV-negative,
HCV-positive mothers14,15. A number of investi-
gators have found that increasing viral titers
of hepatitis C are associated with a greater risk
of vertical transmission15–18, Co-infection with
HIV may allow higher hepatitis C viral titers
through immunosuppression or there may be
some more direct mechanism affecting hepatitis C
virus infectivity19. Any pregnant woman infected
with either HIV or hepatitis C should undergo
testing for the other disease.
Univariate analysis revealed strong associa-
tions of hepatitis C with any illicit drug use,
intravenous drug use and nasal drug use. These
relationships failed to achieve statistical signifi-
cance on multiple logistic regression analysis.
This was probably due to the small numbers
of hepatitis C-positive patients in our study and
because most of the HIV-positive cases were also
drug users. Many previous studies have found
illicit drug use to be a strong risk factor for
hepatitis C infection4–7,11,17,20–31. The method of
acquisition of hepatitis C via intranasal drug use is
unclear. It has been suggested4 that epistaxis and
shared devices might be a method of blood-
borne exposure or alternatively that intranasal
drug use is a surrogate marker for other high-risk
behaviors that patients are unwilling to report.
Of interest in this regard, one study which
mailed anonymous questionnaires to newly
diagnosed hepatitis C patients found that 99.8%
(466/467) admitted to at least one parenteral risk
factor31. Another paper found that almost half
of their hepatitis C-positive pregnant women
had not confessed a history of intravenous drug
use to their midwife on intake, but did so only
laterwhenconfrontedwiththeirpositivestatus32.
The association of hepatitis B with hepatitis C
was much weaker, and disappeared completely
on multivariate analysis. Hepatitis B can be
spread through either sexual contact or paren-
teral exposure. The other STDs we examined
(gonorrhea,chlamydia,syphilis)arealmostentirely
contractedthroughsexualcontactwithaninfected
partner. These three diseases all had a ‘negative’
correlation with hepatitis C, although this only
reached statistical significance for women testing
positive for chlamydia. Sexual transmission of
hepatitis C seems to be inefficient. Previous
studies have found that the majority of sexual
partners of hepatitis C patients are not infected
with hepatitis C2,3,7,31,33–36. One group of investi-
gators3 found ‘no’ cases of sexual transmission
in couples co-habitating for less than 10 years.
Hepatitis C virus has not been detected in the
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groups of investigators35,38 both found that about
75% of sexual partners who tested positive for
hepatitis C had their own parenteral risk factors.
Together with this background information, our
finding of the lack of an association between
hepatitis C and those STDs which are trans-
mitted sexually – not parenterally – in most cases
(gonorrhea, chlamydia, syphilis) adds support to
the concept that hepatitis C is ‘not’ transmitted
efficiently through sexual contact.
Identification of hepatitis C infection in
asymptomatic pregnant women is important for
a number of reasons. One is the availability of
promising new multi-drug treatment regimens
which may significantly improve the long-term
prognosis for patients with chronic active hepatitis
C infection. A second reason is the risk of
vertical transmission. Most authors have found
few or no cases of infected children when their
mothers had negative or low hepatitis C RNA
titers, but significantly greater risks of an affected
childinwomenwithhighRNAtitersonquantita-
tive PCR testing14,16–18,39–43. Infants infected with
hepatitis C during pregnancy or childbirth have
been reported to develop severe clinical hepatitis,
jaundice or death39. Thus, the identification of
pregnant women with hepatitis C (and possibly
viralRNAtiters)allowsdiscussionwiththepatient
about the risks of delivering a child with perinatal
hepatitis C infection. The third reason is that the
identification of asymptomatic hepatitis C infec-
tion allows for effective counseling. As endorsed
by the CDC, a variety of measures designed to
minimize other hepatic insults should be recom-
mended to ‘all’ patients infected with hepatitis C:
completeavoidanceofalcohol,vaccinationagainst
hepatitis A and B and avoidance of medications or
herbs with potential hepatotoxicity. Elimination
or minimization of other hepatotoxic insults
shouldamelioratetheeffectsofchronichepatitisC
infection and lead to less long-term morbidity
and mortality.
One can develop two possible approaches
for hepatitis C screening in obstetric patients.
The first is to screen only high-risk groups.
Studies from outside the US have usually
reported that the pregnant population is not at
higher risk for hepatitis C than the local
population10,13,32,39,44–46. Most previous studies
from within the US(which have looked at
inner city clinic populations) have found that this
group of obstetric patients are indeed at signifi-
cantly greater risk for hepatitis C infection11,12,47.
Reported prevalences have ranged from 3.6
to 5.2%, much higher than the general US
population (1.8%). One study from Germany48
also noted a higher risk for hepatitis C in clinic
versus private patients. Our study attempted to
use STD infection as a surrogate marker of
high-risk behavior which would identify a group
at increased risk for hepatitis C. (While we did
identify a group at high risk for hepatitis C, we
cannot be certain that this approach has actually
worked until we ascertain the background
prevalence in our population via a general
screening program.) Careful analysis of our data
has revealed that the elevated risk was mainly
confined to older women, drug users and those
who tested positive for HIV or hepatitis B.
Younger women who did not abuse drugs, but
testedpositiveforgonorrhea,chlamydiaorsyphilis
were not at higher risk for hepatitis C infection.
Based on our study then, one could limit
hepatitis C screening to obstetric clinic patients
aged 25 years or more, drug users or those
testing positive for HIV or hepatitis B.
One can also make a good argument for
universal screening of all pregnant women. The
expected yield of 1.8% (general USpopulation)
is greater than the yield of other commonly
recommended prenatal tests. The main argument
against universal screening of pregnant women is
that there are as yet no clear measures that
have been proven to decrease the low (about 5%)
but significant risk of vertical transmission.
Although there seems to be less transmission
when viral titers are low or undetectable, it
remains to be proven that lowering those titers
with medical therapy during pregnancy will
reduce transmission. At the current time, there is
inadequate literature to support any obstetric
intervention to decrease vertical transmission.
Studies examining the mode of delivery have had
conflicting results, with some showing a lower risk
of vertical spread with Cesarean delivery14,18,43,
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rates when Cesarean delivery was utilized40,41.
Detection of viral RNA in children within 3 days
of birth suggests that at least some cases of
vertical transmission occur in utero42. Thus, it is not
at all clear that performing an elective Cesarean
delivery will reduce vertical transmission of
hepatitis C virus.
Among STD-infected, inner city pregnant
women, those aged 25 years or over, drug users
or women with positive tests for HIV or hepatitis
B are at high risk for hepatitis C infection and
should be screened. Further study is needed to
best define the at-risk population and to decide
whether routine universal hepatitis C screening
is warranted.
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